Valuation: Arcus Biosciences, Inc.

Market Cap 3.56B 3.11B 2.87B 2.63B 5B 343B 5.09B 34.16B 13.41B 168B 13.38B 13.09B 578B P/E 2026 *
-7.71x
P/E 2027 * -8.4x
Enterprise Value 2.94B 2.57B 2.37B 2.17B 4.13B 283B 4.2B 28.2B 11.07B 138B 11.05B 10.8B 477B EV / Sales 2026 *
34.6x
EV / Sales 2027 * 35.5x
Free-Float
70.85%
Yield 2026 *
-
Yield 2027 * -
1 day-1.09%
1 week-7.37%
Current month-9.11%
1 month+17.73%
3 months+21.77%
6 months+14.09%
Current year+17.58%
1 week 27.21
Extreme 27.21
30.86
1 month 23.31
Extreme 23.31
31.74
Current year 18.52
Extreme 18.515
31.74
1 year 8.84
Extreme 8.84
31.74
3 years 6.5
Extreme 6.5
31.74
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 01/05/2015
Chief Executive Officer 67 01/05/2015
Director of Finance/CFO 53 01/08/2020
Director TitleAgeSince
Chairman 67 01/12/2017
Director/Board Member 65 18/09/2017
Director/Board Member 71 01/05/2015
Date Insider Type Main position Quantity % Market Cap.
07-10Sell

Founder

-20,067 0.0160%
06-24Sell

Founder

-6,431 0.0051%
06-11Fiscal year

General Counsel

68,180 0.0542%
Change 5-day change 1-year change 3-year change Capi.($)
-1.09%-7.37%+190.36%+27.95% 3.56B
-0.17%+1.22%+2.98%+6.80% 50.35B
-0.29%-3.16%+380.69%+591.82% 39.32B
-0.49%-0.68%+29.15%-6.46% 34.69B
+1.53%+0.74%+23.45%+58.54% 34.08B
+1.68%-1.40%+4.23%+27.34% 26.63B
+1.13%+0.60% - - 16.49B
-1.29%-3.12%+65.20%+117.60% 15.31B
+0.43%+0.55%+15.19%+17.46% 13.8B
+2.45%+1.99%+15.09%-30.12% 12.87B
Average +0.39%-1.00%+80.70%+90.10% 24.71B
Weighted average by Cap. +0.37%-0.40%+82.92%+120.84%

Financials

2026 *2027 *
Net sales 85.06M 74.19M 68.45M 62.82M 119M 8.19B 121M 815M 320M 4B 319M 312M 13.79B 93.06M 81.17M 74.89M 68.73M 131M 8.96B 133M 892M 350M 4.37B 349M 342M 15.08B
Net income -456M -398M -367M -337M -640M -43.92B -651M -4.37B -1.72B -21.46B -1.71B -1.68B -73.98B -431M -376M -346M -318M -604M -41.44B -615M -4.13B -1.62B -20.24B -1.62B -1.58B -69.79B
Net Debt -621M -542M -500M -459M -872M -59.8B -887M -5.96B -2.34B -29.21B -2.33B -2.28B -101B -259M -226M -209M -192M -364M -24.96B -370M -2.49B -976M -12.19B -974M -952M -42.04B
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
15/07/26 US$28.02 -1.09% 718,651
14/07/26 US$28.33 +0.93% 801,993
13/07/26 US$28.07 -2.94% 954,774
10/07/26 US$28.92 -3.47% 811,732
09/07/26 US$29.96 -0.99% 753,380
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
28.33USD
Average target price
35.75USD
Spread / Average Target
+26.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RCUS Stock